These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 12168829)

  • 21. Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis.
    Koo KL; Tejwani GA; Abou-Issa H
    Anticancer Res; 1996; 16(4A):1893-8. PubMed ID: 8712718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feeding thiol-containing compounds, derived from vegetables, fails to inhibit N-methylnitrosourea-induced mammary tumorigenesis.
    Cohen LA; Zhao Z; Pittman B; Aliaga C; Lubet R
    Cancer Detect Prev; 2001; 25(3):254-61. PubMed ID: 11425267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dietary folate on the development and progression of mammary tumors in rats.
    Kotsopoulos J; Medline A; Renlund R; Sohn KJ; Martin R; Hwang SW; Lu S; Archer MC; Kim YI
    Carcinogenesis; 2005 Sep; 26(9):1603-12. PubMed ID: 15888495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary effects of conjugated docosahexaenoic acid on N-methyl-N-nitrosourea-induced mammary carcinogenesis in female Sprague-Dawley rats.
    Danbara N; Uehara N; Shikata N; Takada H; Hada T; Tsubura A
    Oncol Rep; 2004 Nov; 12(5):1079-85. PubMed ID: 15492796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
    O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
    J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions between 4-HPR and diet in NMU-induced mammary tumorigenesis.
    Cohen LA; Epstein M; Saa-Pabon V; Meschter C; Zang E
    Nutr Cancer; 1994; 21(3):271-83. PubMed ID: 8072880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of prolonged psychoemotional stress and melatonin on experimental mammary carcinogenesis in female rats.
    Kassayová M; Friedmanová L; Orendás P; Kubatka P; Bojková B; Bobrov N; Ahlersová E; Ahlers I
    Neoplasma; 2007; 54(3):251-5. PubMed ID: 17447859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
    Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
    Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
    Xu WS; Perez G; Ngo L; Gui CY; Marks PA
    Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
    Richon VM; Zhou X; Rifkind RA; Marks PA
    Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
    [No Abstract]   [Full Text] [Related]  

  • 33. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
    Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
    J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
    Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
    Xu Y; Voelter-Mahlknecht S; Mahlknecht U
    Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
    Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
    Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dietary butyrate inhibits NMU-induced mammary cancer in rats.
    Belobrajdic DP; McIntosh GH
    Nutr Cancer; 2000; 36(2):217-23. PubMed ID: 10890033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
    Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequency.
    Swanson SM; Christov K
    Anticancer Res; 2003; 23(4):3207-13. PubMed ID: 12931682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.